 |
|
|
| |
QUALITATIVE PATIENT-PARTICIPANT PERSPECTIVES ON IMPLEMENTATION OF MONTHLY CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB+RPV LA) INJECTABLE IN THE UNITED STATES (CUSTOMIZE)
|
| |
| |
IAS: CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS - (07/20/21)
IAS: CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA - (07/20/21)
IAS: CAB + RPV LA IMPLEMENTATION OUTCOMES AND ACCEPTABILITY OF MONTHLY CLINIC VISITS IMPROVED DURING COVID-19 PANDEMIC ACROSS US HEALTHCARE CLINICS (CUSTOMIZE: HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY) - (07/20/21)
IAS: Long-Acting Treatment: Cabotegravir/rilpivirine; Long-Acting Injectable PrEP HPTN 083, 084 - (08/31/21)
IDWeek 2021 Sept 29-Oct 3
Cindy Garris,1 Larissa Stassek,2 Ronald D'Amico,1 Marybeth Dalessandro,3 Sheila Adkins,4 Blair Thedinger,5 James B. Brock,6 Daniela Chiriboga-Salazar,7 Maggie Czarnogorski1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Evidera, Seattle, WA, USA; 3ViiV Healthcare, Collegeville, PA, USA; 4GlaxoSmithKline, Collegeville, PA, USA; 5KC CARE Health Center, Kansas City, MO, USA; 6University of Mississippi Medical Center, Jacksonville, MS, USA; 7University of Florida at Jacksonville, Jacksonville, FL, USA
|
| |
|
|
|
|
|
